JP6926065B2 - 癌を治療するための方法 - Google Patents

癌を治療するための方法 Download PDF

Info

Publication number
JP6926065B2
JP6926065B2 JP2018509731A JP2018509731A JP6926065B2 JP 6926065 B2 JP6926065 B2 JP 6926065B2 JP 2018509731 A JP2018509731 A JP 2018509731A JP 2018509731 A JP2018509731 A JP 2018509731A JP 6926065 B2 JP6926065 B2 JP 6926065B2
Authority
JP
Japan
Prior art keywords
rad1901
treatment
dose
tumor
erα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018509731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514593A (ja
JP2018514593A5 (enExample
Inventor
ガーナー，フィオナ
ハタスリー，ガリー
Original Assignee
ラジウス ファーマシューティカルズ，インコーポレイテッド
ラジウス ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラジウス ファーマシューティカルズ，インコーポレイテッド, ラジウス ファーマシューティカルズ，インコーポレイテッド filed Critical ラジウス ファーマシューティカルズ，インコーポレイテッド
Publication of JP2018514593A publication Critical patent/JP2018514593A/ja
Publication of JP2018514593A5 publication Critical patent/JP2018514593A5/ja
Priority to JP2021073337A priority Critical patent/JP7262508B2/ja
Application granted granted Critical
Publication of JP6926065B2 publication Critical patent/JP6926065B2/ja
Priority to JP2023009598A priority patent/JP7696378B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018509731A 2015-04-29 2016-04-29 癌を治療するための方法 Active JP6926065B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021073337A JP7262508B2 (ja) 2015-04-29 2021-04-23 癌を治療するための方法
JP2023009598A JP7696378B2 (ja) 2015-04-29 2023-01-25 癌を治療するための方法

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US201562154699P 2015-04-29 2015-04-29
US62/154,699 2015-04-29
US201562155451P 2015-04-30 2015-04-30
US62/155,451 2015-04-30
US201562158469P 2015-05-07 2015-05-07
US62/158,469 2015-05-07
US201562192940P 2015-07-15 2015-07-15
US201562192944P 2015-07-15 2015-07-15
US62/192,940 2015-07-15
US62/192,944 2015-07-15
US201562252085P 2015-11-06 2015-11-06
US62/252,085 2015-11-06
US201562252916P 2015-11-09 2015-11-09
US62/252,916 2015-11-09
US201562265774P 2015-12-10 2015-12-10
US201562265658P 2015-12-10 2015-12-10
US201562265663P 2015-12-10 2015-12-10
US201562265696P 2015-12-10 2015-12-10
US62/265,663 2015-12-10
US62/265,658 2015-12-10
US62/265,774 2015-12-10
US62/265,696 2015-12-10
US201662323572P 2016-04-15 2016-04-15
US201662323576P 2016-04-15 2016-04-15
US62/323,576 2016-04-15
US62/323,572 2016-04-15
PCT/US2016/030317 WO2016176665A1 (en) 2015-04-29 2016-04-29 Methods of treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021073337A Division JP7262508B2 (ja) 2015-04-29 2021-04-23 癌を治療するための方法

Publications (3)

Publication Number Publication Date
JP2018514593A JP2018514593A (ja) 2018-06-07
JP2018514593A5 JP2018514593A5 (enExample) 2019-05-30
JP6926065B2 true JP6926065B2 (ja) 2021-08-25

Family

ID=57198783

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2017556627A Active JP7019422B2 (ja) 2015-04-29 2016-04-29 癌を治療するための方法
JP2018509731A Active JP6926065B2 (ja) 2015-04-29 2016-04-29 癌を治療するための方法
JP2018509732A Active JP6926066B2 (ja) 2015-04-29 2016-04-29 癌を治療するための方法
JP2021052305A Active JP7146992B2 (ja) 2015-04-29 2021-03-25 癌を治療するための方法
JP2021073337A Active JP7262508B2 (ja) 2015-04-29 2021-04-23 癌を治療するための方法
JP2022150560A Active JP7516472B2 (ja) 2015-04-29 2022-09-21 癌を治療するための方法
JP2023009598A Active JP7696378B2 (ja) 2015-04-29 2023-01-25 癌を治療するための方法
JP2024107407A Active JP7745708B2 (ja) 2015-04-29 2024-07-03 癌を治療するための方法
JP2025153179A Pending JP2025170141A (ja) 2015-04-29 2025-09-16 癌を治療するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017556627A Active JP7019422B2 (ja) 2015-04-29 2016-04-29 癌を治療するための方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2018509732A Active JP6926066B2 (ja) 2015-04-29 2016-04-29 癌を治療するための方法
JP2021052305A Active JP7146992B2 (ja) 2015-04-29 2021-03-25 癌を治療するための方法
JP2021073337A Active JP7262508B2 (ja) 2015-04-29 2021-04-23 癌を治療するための方法
JP2022150560A Active JP7516472B2 (ja) 2015-04-29 2022-09-21 癌を治療するための方法
JP2023009598A Active JP7696378B2 (ja) 2015-04-29 2023-01-25 癌を治療するための方法
JP2024107407A Active JP7745708B2 (ja) 2015-04-29 2024-07-03 癌を治療するための方法
JP2025153179A Pending JP2025170141A (ja) 2015-04-29 2025-09-16 癌を治療するための方法

Country Status (14)

Country Link
US (12) US20180169101A1 (enExample)
EP (4) EP3288383A4 (enExample)
JP (9) JP7019422B2 (enExample)
KR (9) KR102682763B1 (enExample)
CN (5) CN113750091B (enExample)
AU (3) AU2016256470B2 (enExample)
BR (3) BR112017023269A2 (enExample)
CA (3) CA2984357A1 (enExample)
HK (3) HK1251409A1 (enExample)
IL (10) IL255148B2 (enExample)
MX (6) MX393599B (enExample)
RU (3) RU2737496C2 (enExample)
SG (4) SG11201708860SA (enExample)
WO (3) WO2016176666A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021105064A (ja) * 2015-04-29 2021-07-26 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
MX386677B (es) 2016-02-15 2025-03-19 Sanofi Sa Derivados de 6,7-dihidro-5h-benzo[7]anuleno como moduladores de receptores de estrogenos
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
LT3518911T (lt) * 2016-09-27 2021-12-10 Radius Pharmaceuticals, Inc. Rad1901, skirtas naudoti kiaušidžių vėžio gydymui
IL284875B (en) 2016-10-11 2022-07-01 Univ Duke Zofoxifene treatment for breast cancer
JP6946430B2 (ja) 2016-11-17 2021-10-06 サノフイＳａｎｏｆｉ 新規の置換ｎ−（３−フルオロプロピル）−ピロリジン化合物、それを製造するための方法、およびその治療的使用
KR102881465B1 (ko) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
RU2764724C2 (ru) * 2017-03-16 2022-01-19 ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. Комбинированная терапия для лечения рака молочной железы
US12012421B2 (en) 2017-07-07 2024-06-18 Hoffmann-La Roche Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
WO2019097426A1 (en) 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib
US12012420B2 (en) 2017-11-21 2024-06-18 Hoffmann-La Roche, Inc. Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
CN111386113A (zh) 2017-12-01 2020-07-07 诺华股份有限公司 包含lsz102和阿培利司的药物组合
EP3773524B1 (en) 2018-04-10 2025-04-09 Duke University Lasofoxifene for the treatment of er+ breast cancer carrying the mutation d538g or y537s
CN110585429B (zh) * 2018-06-12 2022-10-21 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途
SG11202013177WA (en) * 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
AR116299A1 (es) 2018-09-07 2021-04-21 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
AU2019388900B2 (en) 2018-11-30 2025-09-04 Radius Pharmaceuticals, Inc. Elacestrant in combination with abemaciclib in women with breast cancer
JP7497353B2 (ja) * 2018-12-06 2024-06-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法
UA130036C2 (uk) * 2018-12-06 2025-10-22 Радіус Фармасеутікалс, Інк. Спосіб лікування стійкого до інгібітору cdk4/6 раку
BR112021011222A2 (pt) * 2018-12-12 2021-08-24 Chemocentryx, Inc. Inibidores de cxcr7 para o tratamento de câncer
KR20210127961A (ko) 2019-02-12 2021-10-25 래디어스 파마슈티컬스, 인코포레이티드 방법 및 화합물
JP2022531898A (ja) * 2019-05-09 2022-07-12 サノフイ 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸
CN114302722A (zh) 2019-07-07 2022-04-08 奥列马制药公司 雌激素受体拮抗剂方案
KR102341347B1 (ko) * 2019-11-28 2021-12-20 의료법인 성광의료재단 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
WO2021178846A1 (en) * 2020-03-06 2021-09-10 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
CN120267673A (zh) * 2020-04-24 2025-07-08 阿斯利康(瑞典)有限公司 用于治疗癌症的剂量方案
AU2021272100B2 (en) 2020-05-12 2024-09-12 Genentech, Inc. Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
MX2023001572A (es) * 2020-08-05 2023-05-08 Aizant Drug Res Solutions Private Limited Formas farmaceuticas sólidas de palbociclib.
CA3202592A1 (en) * 2020-12-14 2022-06-23 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CA3210479A1 (en) * 2021-02-16 2022-08-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
CN113662942B (zh) * 2021-08-19 2023-02-07 中国人民解放军陆军军医大学第一附属医院 药物组合物及其在smo突变性髓母细胞瘤中的应用
WO2023064519A1 (en) 2021-10-14 2023-04-20 Teva Pharmaceuticals International Gmbh Solid state forms of elacestrant and processes for preparation thereof
DE102021130035A1 (de) 2021-11-17 2023-05-17 USound GmbH MEMS-Schallwandler mit einer gekrümmten Kontur eines Kragarmelements
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2024104268A1 (zh) * 2022-11-15 2024-05-23 苏州科睿思制药有限公司 艾拉司群二盐酸盐的共晶及其制备方法和用途
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법
EP4574811A1 (en) 2023-12-22 2025-06-25 Sandoz Ag Crystalline forms of elacestrant dihydrochloride
WO2025158416A1 (en) 2024-01-25 2025-07-31 Assia Chemical Industries Ltd. Solid state forms of elacestrant and processes for preparation thereof

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939346A1 (de) 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
DE19538687A1 (de) 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CZ298701B6 (cs) 1997-09-09 2007-12-27 F. Hoffman-La Roche Ag Lécivo pro hojení kostí a reparaci zlomenin
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6050988A (en) 1997-12-11 2000-04-18 Alza Corporation Device for enhancing transdermal agent flux
EP1037686B1 (en) 1997-12-11 2005-08-17 Alza Corporation Device for enhancing transdermal agent flux
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6091975A (en) 1998-04-01 2000-07-18 Alza Corporation Minimally invasive detecting device
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2001036039A2 (en) 1999-11-17 2001-05-25 Novartis Ag Iontophoretic transdermal delivery of peptides
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US20010044431A1 (en) 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
WO2002011768A1 (en) 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
JP2004506712A (ja) 2000-08-23 2004-03-04 アクゾ・ノベル・エヌ・ベー 医療に使用するための１０−アリール−１１Ｈ−ベンゾ［ｂ］フルオレン誘導体および類似体
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
ES2322023T3 (es) 2000-10-26 2009-06-16 Alza Corporation Dispositivos de administracion transdermica de farmacos que presentan unas microprotuberancias recubiertas.
US7963935B2 (en) 2001-04-20 2011-06-21 Alza Corporation Microprojection array having a beneficial agent containing coating
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
US6881203B2 (en) 2001-09-05 2005-04-19 3M Innovative Properties Company Microneedle arrays and methods of manufacturing the same
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
PT1465535E (pt) 2001-12-20 2008-02-08 Alza Corp Microprojecções que perfuram a pele tendo controlo de profundidade de perfuração
EP1465619A1 (en) 2002-01-14 2004-10-13 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
CA2472956A1 (en) 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
CA2496618A1 (en) 2002-05-23 2003-12-04 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
EP1539212A4 (en) 2002-07-12 2007-05-02 Medarex Inc METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS
WO2004009172A1 (en) 2002-07-19 2004-01-29 3M Innovative Properties Company Microneedle devices and microneedle delivery apparatus
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
KR20050059258A (ko) 2002-10-14 2005-06-17 노보 노르디스크 에이/에스 Ｇｌｐ-2 화합물, 제제, 및 그것의 사용
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
AU2002359391A1 (en) 2002-11-01 2004-07-29 Amgen, Inc. Modulators of receptors for parathyrois hormone and parathyroid hormone-related protein
EP1577288B1 (en) * 2002-12-26 2014-07-23 Eisai R&D Management Co., Ltd. Selective estrogen receptor modulators
EP1636167A2 (en) 2003-06-10 2006-03-22 SmithKline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
JP2007500245A (ja) 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
PL1638468T3 (pl) 2003-06-30 2008-01-31 Alza Corp Sposób powlekania mikrowystępów do przekłuwania skóry
WO2005004842A2 (en) 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
WO2005014034A1 (en) 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
US7141544B2 (en) 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
KR20070001886A (ko) 2003-10-28 2007-01-04 알자 코포레이션 치료용 펩타이드 및 단백질의 폴리머 컨쥬게이트의 피복된미세돌출부를 통한 전달
EP1680154B1 (en) 2003-10-31 2012-01-04 ALZA Corporation Self-actuating applicator for microprojection array
AU2004292954A1 (en) 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
EP1687274A1 (en) 2003-11-20 2006-08-09 Warner-Lambert Company LLC Androgen receptor modulators
CA2546723A1 (en) 2003-11-21 2005-06-09 Alza Corporation Ultrasound assisted transdermal vaccine delivery method and system
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
KR101536701B1 (ko) 2004-01-07 2015-07-14 앙도르쉐르슈 인코포레이티드 헬릭스 12 배향형 스테로이드계 약학 제품
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
WO2005099707A1 (en) 2004-04-08 2005-10-27 Merck & Co., Inc. 17 beta-acetamide-4-azasteroids as androgen receptor modulators
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
EP1747193A1 (en) 2004-05-11 2007-01-31 Pfizer Products Incorporated Benzonitrile derivatives to treat musculoskeletal frailty
EP1744683B1 (en) 2004-05-13 2016-03-16 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
EP1765406A4 (en) 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
US20090069226A1 (en) 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
AU2005310238A1 (en) 2004-10-29 2006-06-08 Merck Sharp & Dohme Corp. N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
KR101224257B1 (ko) 2004-11-18 2013-01-18 쓰리엠 이노베이티브 프로퍼티즈 컴파니 마이크로니들 어레이를 코팅하기 위한 마스킹 방법
CA2587780A1 (en) 2004-11-18 2006-05-26 Transpharma Medical Ltd. Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
AU2006206272A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
US20080194536A1 (en) 2005-04-15 2008-08-14 Marlys Hammond Cyanoarylamines
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
WO2006133216A2 (en) 2005-06-06 2006-12-14 Smithkline Beecham Corporation 4-substituted arylamine derivatives and their use in pharmaceutical compositions
US20090227571A1 (en) 2005-07-01 2009-09-10 Ligand Pharmaceuticals Incorporated Androgen Receptor Modulator Compounds and Methods
US20070021216A1 (en) 2005-07-19 2007-01-25 Sony Ericsson Mobile Communications Ab Seamless gaming method and apparatus
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
US8900180B2 (en) 2005-11-18 2014-12-02 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
US8632801B2 (en) 2005-12-28 2014-01-21 Alza Corporation Stable therapeutic formulations
CA2680690A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
US8779004B2 (en) 2006-04-20 2014-07-15 Amgen, Inc. Stable emulsion formulations
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
JP5362552B2 (ja) 2006-04-20 2013-12-11 ヴェロシス，インク． マイクロチャネルプロセス技術を用いて非ニュートン流体を処理し、および／または形成させるためのプロセス
CN101085743B (zh) 2006-06-06 2012-02-15 浙江大德药业集团有限公司 含氟烷氧基康普立停衍生物及制法和用途
ES2436028T3 (es) 2006-06-23 2013-12-26 Radius Health, Inc. Tratamiento de síntomas vasomotores con moduladores selectivos de receptores de estrógeno
AR061980A1 (es) 2006-07-12 2008-08-10 Univ Tennessee Res Foundation Acilanilidas sustituidas y metodos para su utilizacion
KR101264820B1 (ko) 2006-08-24 2013-05-22 유니버시티 오브 테네시 리서치 파운데이션 치환된 아실아닐리드 및 그의 사용 방법
AR062522A1 (es) 2006-08-25 2008-11-12 Ares Trading Sa Tratamiento de desordenes en cartilagos
CN1927815A (zh) 2006-09-25 2007-03-14 天津理工大学 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
US20100030100A1 (en) 2007-02-06 2010-02-04 Hisamitsu Pharmaceutical Co., Inc. Microneedle Device For Diagnosis Of Allergy
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
EP2146689B1 (en) 2007-04-16 2020-08-12 Corium, Inc. Solvent-cast microneedle arrays containing active
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
CA2688049A1 (en) 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
MX2009013575A (es) 2007-06-12 2010-07-02 Schering Corp Biomarcador de histona h2ax (hh2ax) para sensibilidad de inhibidores de farnesil proteina transferasa.
WO2008157425A2 (en) 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US20120150023A1 (en) 2007-08-06 2012-06-14 Kaspar Roger L Microneedle arrays for active agent delivery
CN101808588B (zh) 2007-09-28 2012-12-19 贝尔法斯特女王大学 递送装置及方法
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
EP2052736A1 (en) 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
WO2009065126A2 (en) 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
US20110124617A1 (en) * 2008-05-09 2011-05-26 Lyttle C Richard Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
US20100092566A1 (en) 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
MX2011004453A (es) 2008-11-04 2011-08-12 Aska Pharm Co Ltd Composicion acuosa que contiene hormona foliculo estimulante.
KR20190064676A (ko) 2008-11-18 2019-06-10 쓰리엠 이노베이티브 프로퍼티즈 컴파니 중공 마이크로니들 어레이
WO2010074239A1 (ja) 2008-12-26 2010-07-01 久光製薬株式会社 マイクロニードルデバイス
US20100203014A1 (en) 2009-02-04 2010-08-12 Aegis Therapeutics Llc Zwitterionic buffered acidic peptide and protein formulations
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
US20110006458A1 (en) 2009-04-24 2011-01-13 Corium International, Inc. Methods for manufacturing microprojection arrays
WO2011014514A1 (en) 2009-07-31 2011-02-03 3M Innovative Properties Company Hollow microneedle arrays
WO2011051916A2 (en) 2009-11-02 2011-05-05 Universite De Geneve Stabilized protein formulations and use thereof
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
CN101912600B (zh) 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
CA2798145C (en) 2010-05-04 2022-10-18 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
WO2011150144A2 (en) 2010-05-28 2011-12-01 3M Innovative Properties Company Aqueous formulations for coating microneedle arrays
SG186333A1 (en) * 2010-06-16 2013-01-30 Endorech Inc Methods of treating or preventing estrogen-related diseases
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
EP2680871A4 (en) 2011-03-01 2015-04-22 Sloan Kettering Inst Cancer SYMBOLS HORMONE ANALOGUE, COMPOSITIONS THEREOF AND USES THEREOF
EP3332799A1 (en) 2011-04-22 2018-06-13 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
BR112014013151B1 (pt) 2011-11-30 2022-02-08 3M Innovative Properties Company Dispositivo médico compreendendo microagulhas incluindo um agente terapêutico peptídeo e um aminoácido, métodos para produzir o dispositivo e método para estabilizar um agente terapêutico peptídeo
GB201217439D0 (en) 2012-09-28 2012-11-14 Topotarget As Combination therapy
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203129A1 (en) * 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN104436194B (zh) 2013-09-18 2018-03-30 北京大学 具有协同增效作用的抗癌组合物
WO2015113062A1 (en) * 2014-01-27 2015-07-30 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery
CA2940576A1 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
FI3834824T3 (fi) * 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
AR104068A1 (es) * 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
MX393599B (es) 2015-04-29 2025-03-19 Radius Pharmaceuticals Inc Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021105064A (ja) * 2015-04-29 2021-07-26 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
JP2023052631A (ja) * 2015-04-29 2023-04-11 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
JP7262508B2 (ja) 2015-04-29 2023-04-21 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
JP7696378B2 (ja) 2015-04-29 2025-06-20 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法

Also Published As

Publication number Publication date
US20220110890A1 (en) 2022-04-14
SG10202104177VA (en) 2021-05-28
JP7745708B2 (ja) 2025-09-29
CN113750091A (zh) 2021-12-07
KR102676705B1 (ko) 2024-06-18
RU2745678C2 (ru) 2021-03-30
MX2021005561A (es) 2022-07-01
KR102871388B1 (ko) 2025-10-14
IL307983A (en) 2023-12-01
IL307983B1 (en) 2025-11-01
JP2018518529A (ja) 2018-07-12
IL255261B2 (en) 2024-03-01
IL323926A (en) 2025-12-01
KR20180043202A (ko) 2018-04-27
IL255148A0 (en) 2017-12-31
IL310069B2 (en) 2025-08-01
KR20240097966A (ko) 2024-06-27
CA2984195A1 (en) 2016-11-03
NZ737819A (en) 2024-10-25
KR102871408B1 (ko) 2025-10-14
HK1251407A1 (zh) 2019-02-01
KR20250153309A (ko) 2025-10-24
CA2984200A1 (en) 2016-11-03
CA2984357A1 (en) 2016-11-03
WO2016176666A1 (en) 2016-11-03
KR102871380B1 (ko) 2025-10-14
AU2016256470A1 (en) 2017-12-14
JP2018514549A (ja) 2018-06-07
IL319266A (en) 2025-04-01
WO2016176665A1 (en) 2016-11-03
NZ737822A (en) 2024-10-25
JP7262508B2 (ja) 2023-04-21
BR112017023233A2 (en) 2018-11-06
JP7146992B2 (ja) 2022-10-04
IL323924A (en) 2025-12-01
MX2017013794A (es) 2018-08-15
JP2018514593A (ja) 2018-06-07
MX2021003389A (es) 2021-05-28
AU2016256471B2 (en) 2020-09-10
KR20240110098A (ko) 2024-07-12
US20250367141A1 (en) 2025-12-04
HK1251409A1 (zh) 2019-02-01
SG11201708858WA (en) 2017-11-29
IL297369B2 (en) 2024-06-01
IL255148B2 (en) 2023-04-01
CN108024540B (zh) 2021-09-17
KR102676629B1 (ko) 2024-06-18
KR20180011780A (ko) 2018-02-02
JP6926066B2 (ja) 2021-08-25
US20180214393A1 (en) 2018-08-02
MX384605B (es) 2025-03-14
MX394676B (es) 2025-03-24
MX2017013802A (es) 2018-08-15
MX2017013801A (es) 2018-08-15
US20180153828A1 (en) 2018-06-07
IL255261B1 (en) 2023-11-01
RU2737496C2 (ru) 2020-12-01
CN108024541A (zh) 2018-05-11
JP2021105064A (ja) 2021-07-26
JP2023052631A (ja) 2023-04-11
CN113288887A (zh) 2021-08-24
JP7019422B2 (ja) 2022-02-15
US20200038343A1 (en) 2020-02-06
MX2021004881A (es) 2021-07-21
RU2017140674A (ru) 2019-05-29
US20250367140A1 (en) 2025-12-04
KR20240095372A (ko) 2024-06-25
RU2017140676A (ru) 2019-05-29
NZ737825A (en) 2024-10-25
CN108024540A (zh) 2018-05-11
HK1251408A1 (zh) 2019-02-01
SG11201708860SA (en) 2017-11-29
CN108024541B (zh) 2021-07-20
MX384908B (es) 2025-03-14
JP2021102640A (ja) 2021-07-15
EP3288383A1 (en) 2018-03-07
IL310069A (en) 2024-03-01
US20180169101A1 (en) 2018-06-21
US20240091177A1 (en) 2024-03-21
BR112017023228A2 (en) 2018-11-06
US20200368183A1 (en) 2020-11-26
IL297369B1 (en) 2024-02-01
US20220339126A1 (en) 2022-10-27
AU2016256469A1 (en) 2017-12-14
US12263141B2 (en) 2025-04-01
BR112017023269A2 (en) 2018-11-06
RU2747228C2 (ru) 2021-04-29
IL255261A0 (en) 2017-12-31
RU2017140676A3 (enExample) 2019-09-27
KR20250152678A (ko) 2025-10-23
IL310069B1 (en) 2025-04-01
EP3288382A1 (en) 2018-03-07
EP4039253A1 (en) 2022-08-10
IL255189B1 (en) 2023-12-01
EP3288383A4 (en) 2019-01-23
SG11201708861VA (en) 2017-11-29
CA2984200C (en) 2024-03-19
AU2016256469A8 (en) 2017-12-21
MX393599B (es) 2025-03-19
US11819480B2 (en) 2023-11-21
AU2016256470B2 (en) 2020-10-15
EP3294065A4 (en) 2019-03-20
WO2016176664A1 (en) 2016-11-03
US20200046655A1 (en) 2020-02-13
US11413258B2 (en) 2022-08-16
CA2984195C (en) 2023-10-24
RU2017140675A3 (enExample) 2019-09-27
KR102682763B1 (ko) 2024-07-05
CN108135177A (zh) 2018-06-08
RU2017140675A (ru) 2019-05-29
CN113750091B (zh) 2025-03-11
EP3294065A1 (en) 2018-03-21
IL255189A0 (en) 2017-12-31
US20240099996A1 (en) 2024-03-28
IL307981A (en) 2023-12-01
JP2024120996A (ja) 2024-09-05
AU2016256471A1 (en) 2017-12-21
JP7696378B2 (ja) 2025-06-20
IL297369A (en) 2022-12-01
KR20180042155A (ko) 2018-04-25
IL255189B2 (en) 2024-04-01
CN108135177B (zh) 2021-06-01
JP7516472B2 (ja) 2024-07-16
EP3288382A4 (en) 2019-01-30
AU2016256469B2 (en) 2020-12-10
RU2017140674A3 (enExample) 2019-09-27
IL255148B (en) 2022-12-01
IL307981B1 (en) 2025-11-01
KR20250152679A (ko) 2025-10-23
JP2022172039A (ja) 2022-11-14
JP2025170141A (ja) 2025-11-14

Similar Documents

Publication Publication Date Title
JP7696378B2 (ja) 癌を治療するための方法
HK40079056A (en) Methods of treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210423

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210426

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210615

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210804

R150 Certificate of patent or registration of utility model

Ref document number: 6926065

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250